LifeMD (LFMD) to Release Quarterly Earnings on Monday

LifeMD (NASDAQ:LFMD) is expected to announce its earnings results after the market closes on Monday, March 10th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $57.43 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

LifeMD Stock Down 3.3 %

NASDAQ:LFMD opened at $4.67 on Friday. The company has a market cap of $202.27 million, a P/E ratio of -7.30 and a beta of 1.50. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The firm’s 50 day moving average is $5.67 and its two-hundred day moving average is $5.38.

Insider Buying and Selling at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the transaction, the chief executive officer now directly owns 2,653,715 shares of the company’s stock, valued at $20,035,548.25. The trade was a 1.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.97% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on LFMD shares. Mizuho assumed coverage on shares of LifeMD in a research note on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target on the stock. KeyCorp dropped their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Finally, Lake Street Capital assumed coverage on shares of LifeMD in a report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.